Savara’s (SVRA) Buy Rating Reiterated at HC Wainwright

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 106.19% from the stock’s current price. HC Wainwright also issued estimates for Savara’s Q1 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

SVRA has been the subject of several other research reports. Wells Fargo & Company started coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Savara Stock Performance

Shares of SVRA opened at $2.91 on Friday. The company’s 50 day simple moving average is $2.72 and its 200-day simple moving average is $3.26. Savara has a 12-month low of $2.26 and a 12-month high of $5.34. The firm has a market cap of $499.41 million, a PE ratio of -6.77 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. As a group, equities analysts predict that Savara will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of large investors have recently added to or reduced their stakes in SVRA. Vestal Point Capital LP lifted its holdings in shares of Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock valued at $33,079,000 after purchasing an additional 2,685,000 shares in the last quarter. Rosalind Advisors Inc. purchased a new stake in Savara in the 4th quarter valued at approximately $8,151,000. Nantahala Capital Management LLC grew its holdings in Savara by 45.2% during the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock valued at $23,103,000 after buying an additional 2,344,308 shares during the last quarter. Emerald Advisers LLC purchased a new position in Savara during the fourth quarter worth $7,161,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company’s stock worth $20,983,000 after acquiring an additional 2,275,000 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.